Polar Asset Management Partners Inc. Acquires Shares of 47,564 DexCom, Inc. (NASDAQ:DXCM)

Polar Asset Management Partners Inc. acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 47,564 shares of the medical device company’s stock, valued at approximately $3,699,000.

Several other institutional investors also recently bought and sold shares of DXCM. Private Trust Co. NA grew its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. acquired a new stake in shares of DexCom in the fourth quarter valued at about $33,000. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC grew its position in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. This represents a 4.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,926 shares of company stock valued at $4,734,384. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $85.67 on Friday. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26. The business’s fifty day simple moving average is $71.70 and its 200-day simple moving average is $77.51. The firm has a market cap of $33.59 billion, a PE ratio of 59.91, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the company earned $0.32 EPS. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DXCM. Piper Sandler dropped their target price on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Mizuho initiated coverage on DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price target for the company. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.